Cerevance

NETSseq, CNS therapeutics, cell type-specific therapies

modulatingsmall molecule

cerevance.com·Cambridge, United Kingdom·Series C Plus·$219M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-CZAC

Summary · Eternal Search editorial

Cerevance NETSseq, CNS therapeutics, cell type-specific therapies

Cerevance is developing differentiated product candidates for neurodegenerative, psychiatric, and CNS-controlled metabolic disorders. Its NETSseq platform is described as providing deeper insight into the human brain to identify novel drug targets. The company’s lead Parkinson’s program, solengepras, is in a pivotal Phase 3 ARISE trial, with topline data expected at the end of Q3 2026.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite15

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Cerevance — Near-term readout · Bottom quartile. Derived deterministically from 7 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.

Source: Deterministic

At a glance

Webcerevance.com

HQCambridge, United Kingdom

StageSeries C Plus

Publications

28 on file

012026Identification of a thermogenic target in the dorsal raphe nucleus for weight management in mice.Nature communications→022026Discovery of Potent, Selective, and Brain-Penetrant Small Molecule CD38 Inhibitors.ACS medicinal chemistry letters→032025NETSseq reveals inflammatory and aging mechanisms in distinct cell types, driving cerebellar decline in ataxia telangiectasia.Frontiers in neuroscience→042024Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment.ACS medicinal chemistry letters→052024Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist—→062024Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist.Bioorganic & medicinal chemistry letters→072024Differential contribution of THIK-1 K+ channels and P2X7 receptors to ATP-mediated neuroinflammation by human microglia.Journal of neuroinflammation→082024CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial.EClinicalMedicine→092024Structural insights into the high basal activity and inverse agonism of the orphan receptor GPR6 implicated in Parkinson's disease.Science signaling→102024Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment—→112023Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor—→122023Characterisation of C101248: A novel selective THIK-1 channel inhibitor for the modulation of microglial NLRP3-inflammasome.Neuropharmacology→132023Author Correction: Pharmacological targeting of glutamatergic neurons within the brainstem for weight reduction.Nature metabolism→142023Discovery of CVN417, a Novel Brain-Penetrant α6-Containing Nicotinic Receptor Antagonist for the Modulation of Motor Dysfunction.Journal of medicinal chemistry→152023Discovery and Characterization of Novel CNS-Penetrant GPR55 Agonists.Journal of medicinal chemistry→162023Discovery of CVN636: A Highly Potent, Selective, and CNS Penetrant mGluR7 Allosteric Agonist.ACS medicinal chemistry letters→172022Synthesis and SAR of novel GPR39 agonists and positive allosteric modulators.Bioorganic & medicinal chemistry letters→182022A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson's Disease.The Journal of pharmacology and experimental therapeutics→192022Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology→202022The two pore potassium channel THIK-1 regulates NLRP3 inflammasome activation.Glia→212022Pharmacological targeting of glutamatergic neurons within the brainstem for weight reduction.Nature metabolism→222021First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate.Journal of medicinal chemistry→232021Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease.The Journal of pharmacology and experimental therapeutics→242020Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease.Frontiers in aging neuroscience→252020Increasing Tau 4R Tau Levels Exacerbates Hippocampal Tau Hyperphosphorylation in the hTau Model of Tauopathy but Also Tau Dephosphorylation Following Acute Systemic Inflammation.Frontiers in immunology→262019SIPA1L2 controls trafficking and local signaling of TrkB-containing amphisomes at presynaptic terminals.Nature communications→272019Tackling gaps in developing life-changing treatments for dementia.Alzheimer's & dementia (New York, N. Y.)→282018AKT signalling selectively regulates PINK1 mitophagy in SHSY5Y cells and human iPSC-derived neurons.Scientific reports→

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Cerevance

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.